08:00-08:05	1: Welcome & Introduction Marc Ferrante, Leuven, Belgium
08:05-09:45	Session 1: Evolving endpoint in IBD clinical trials Javier Gisbert, Madrid, Spain
	08:05-08:25	2: Patient Reported Outcomes Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France
	08:25-08:45	3: Defining endoscopic endpoins Krisztina Gecse, Amsterdam, The Netherlands
	08:45-09:05	4: Cross-sectional imaging Andrea Laghi, Latina, Italy
	09:05-09:25	5: Histologic remission Roger Feakins, London, United Kingdom
	09:25-09:45	6: How endpoints can influence trial design? Walter Reinisch, Vienna, Austria
09:45-10:15	Coffee break
10:15-11:30	Session 2: Comparative effectiveness research (CER) John Mansfield, Newcastle upon Tyne, United Kingdom
	10:15-10:30	7: General principles Jean-Frédéric Colombel, New York, United States
	10:30-10:50	8: What is the value of retrospective CER? Pieter Hindryckx, Ghent, Belgium
	10:50-11:10	9: Head-to-head trials Simon Travis, Oxford, United Kingdom
	11:10-11:30	10: Setting priorities for IBD (discussion) Jean-Frédéric Colombel, New York, United States Pieter Hindryckx, Ghent, Belgium Simon Travis, Oxford, United Kingdom John Mansfield, Newcastle upon Tyne, United Kingdom Elmer Schabel, Bonn, Germany
11:30-11:40	11: Summary & Closing remarks Marc Ferrante, Leuven, Belgium